2023

MAP kinase activating death domain deficiency is a novel cause of impaired lymphocyte cytotoxicity
Schütze K, Groß M, Cornils K, Wustrau K, Schneppenheim S, Lenhartz H, Korenke G, Janka G, Ledig S, Müller I, Ehl S, Lehmberg K
BLOOD ADV. 2023;7(8):1531-1535.

2022

Immune Ablation and Stem Cell Rescue in Two Pediatric Patients with Progressive Severe Chronic Graft-Versus-Host Disease
Kloehn J, Kruchen A, Schütze K, Wustrau K, Schrum J, Müller I
INT J MOL SCI. 2022;23(23):.

2020

Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs)
Hambach J, Riecken K, Cichutek S, Schütze K, Albrecht B, Petry K, Röckendorf J, Baum N, Kröger N, Hansen T, Schuch G, Haag F, Adam G, Fehse B, Bannas P, Koch-Nolte F
CELLS-BASEL. 2020;9(2):.

Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies
Schriewer L, Schütze K, Petry K, Hambach J, Fumey W, Koenigsdorf J, Baum N, Menzel S, Rissiek B, Riecken K, Fehse B, Röckendorf J, Schmid J, Albrecht B, Pinnschmidt H, Ayuk F, Kröger N, Binder M, Schuch G, Hansen T, Haag F, Adam G, Koch-Nolte F, Bannas P
THERANOSTICS. 2020;10(6):2645-2658.

2019

Nanobody-targeting of epidermal growth factor receptor (EGFR) ectodomain variants overcomes resistance to therapeutic EGFR antibodies
Tintelnot J, Baum N, Schultheiss C, Braig F, Trentmann M, Finter J, Fumey W, Bannas P, Fehse B, Riecken K, Schütze K, Bokemeyer C, Rösner T, Valerius T, Peipp M, Koch-Nolte F, Binder M
MOL CANCER THER. 2019;18(4):823-833.

2018

CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells
Schütze K, Petry K, Hambach J, Schuster N, Fumey W, Schriewer L, Rockendorf J, Menzel S, Albrecht B, Haag F, Stortelers C, Bannas P, Koch-Nolte F
FRONT IMMUNOL. 2018;9:2553.

2017

Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivo
Fumey W, Koenigsdorf J, Kunick V, Menzel S, Schütze K, Unger M, Schriewer L, Haag F, Adam G, Oberle A, Binder M, Fliegert R, Guse A, Zhao Y, Cheung Lee H, Malavasi F, Goldbaum F, van Hegelsom R, Stortelers C, Bannas P, Koch-Nolte F
SCI REP-UK. 2017;7(1):14289.

Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection
Oberle A, Brandt A, Alawi M, Langebrake C, Janjetovic S, Wolschke C, Schütze K, Bannas P, Kröger N, Koch-Nolte F, Bokemeyer C, Binder M
HAEMATOLOGICA. 2017;102(9):e368-e370.

2015

Molecular imaging of tumors with nanobodies and antibodies: Timing and dosage are crucial factors for improved in vivo detection
Bannas P, Lenz A, Kunick V, Well L, Fumey W, Rissiek B, Haag F, Schmid J, Schütze K, Eichhoff A, Trepel M, Adam G, Ittrich H, Koch-Nolte F
CONTRAST MEDIA MOL I. 2015;10(5):367-378.

Letzte Aktualisierung aus dem FIS: 23.12.2024 - 23:34 Uhr